New triplet therapy hopes to shrink liver tumors

NCT ID NCT06789757

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of three drugs (atezolizumab, bevacizumab, and memantine) in 19 adults with advanced liver cancer that cannot be removed by surgery. The main goal is to see how many patients have their tumors shrink or disappear. Participants must be newly diagnosed and have not received prior treatment for their current liver cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Inova Health Care Service

    RECRUITING

    Falls Church, Virginia, 22042, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Inova Schar Cancer Institute - Fair Oaks

    RECRUITING

    Fairfax, Virginia, 22033, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••